Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 2, 2012, Pages 221-229

  Belfiglio, Maurizio ^a   Fanizza, Caterina ^a   Tinari, Nicola ^b   Ficorella, Corrado ^c   Iacobelli, Stefano ^b   Natoli, Clara ^b  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Docetaxel; Meta analysis; Metastatic breast cancer; Taxanes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 84857038574     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1091-0     Document Type: Article

References (38)

1. Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G (2008) Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/ HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 13 (4): 361-369. doi: 10.1634/theoncologist.2007-0207 (Pubitemid 351679914)
2. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H (2009) Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 20 (11): 1771-1785. doi: 10.1093/annonc/mdp261
3. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100 (16): 1179-1183. doi: 10.1093/jnci/djn233
4. Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 110 (5): 965-972. doi: 10.1002/cncr.22885 (Pubitemid 47312860)
5. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26 (12): 1987-1992. doi: 10.1200/jco.2007.10.8407
6. Butters DJ, Ghersi D, Wilcken N, Kirk SJ, Mallon PT (2010) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer. Cochrane Database Syst Rev 11: CD003368. doi: 10.1002/14651858.CD003368.pub3
7. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides S, Costa A, Cufer T, Albain KS (2009) International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 101 (17): 1174-1181. doi: 10.1093/jnci/djp235
8. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M (2010) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol 21 (Suppl 5): 15-19. doi: 10.1093/annonc/mdq160
9. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev (2): CD003372. doi: 10.1002/14651858.CD003372.pub3
10. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzalez Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J (1999) Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17 (8): 2341-2354 (Pubitemid 29368232)
11. Di Leo A, Buyse M, Bleiberg H (2004) Is overall survival a realistic primary end point in advanced colorectal cancer studies?Acritical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol 15 (4): 545-549 (Pubitemid 38559586)
12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (7109): 629-634 (Pubitemid 27387172)
13. Force. ESoOE-MT (2007) Metastatic breast cancer. Recommendations proposal from the European school of oncology (ESO)- MBC task force. Breast 16 (1): 9-10
14. Ghersi D, Wilcken N, Simes J, Donoghue E (2005a) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev (2): CD003366. doi: 10.1002/14651858.CD003366.pub2
15. Ghersi D, Wilcken N, Simes RJ (2005b) A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93 (3): 293-301. doi: 10.1038/sj.bjc.6602680 (Pubitemid 43080031)
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327 (7414): 557-560. doi: 10.1136/bmj.327.7414.557 (Pubitemid 37088507)
17. Jemal A, Center MM, DeSantis C, Ward EM (2010a) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19 (8): 1893-1907. doi: 10.1158/1055-9965.epi-10-0437
18. Jemal A, Siegel R, Xu J, Ward E (2010b) Cancer statistics, 2010. CA Cancer J Clin 60 (5): 277-300. doi: 10.3322/caac.20073
19. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23 (24): 5542-5551. doi: 10.1200/jco.2005.02.027
20. Kostler WJ, Brodowicz T, Zielinski CC (2010) Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 102 (3): 207; author reply 207-208. doi: 10.1093/jnci/djp483
21. Lin YC, Chang HK, Chen JS, Wang HM, Yang TS, Liaw CC (2007) A phase II randomized study of two taxanes and cisplatin for metastatic breast cancer after anthracycline: a final analysis. Jpn J Clin Oncol 37 (1): 23-29. doi: 10.1093/jjco/hyl124 (Pubitemid 47090720)
22. Mackey JR, Paterson A, Dirix LY (2002) Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer [abs 137]. Proc Am Soc Clin Oncol 21: 35a
23. Mukai H, Takashima T, Hozumi Y, Watanabe T, Murakami S, Masuda N, Mitsuyama S, Ohmura T, Yajima T, Ohashi Y (2010) Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). Jpn J Clin Oncol 40 (8): 811-814. doi: 10.1093/jjco/hyq054
24. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17 (5): 1413-1424 (Pubitemid 29220847)
25. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21 (6): 968-975 (Pubitemid 46594123)
26. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20 (12): 2812-2823 (Pubitemid 34651510)
27. Pacilio C, Morabito A, Nuzzo F, Gravina A, Labonia V, Landi G, Rossi E, De Maio E, Di Maio M, D'Aiuto G, Botti G, Normanno N, Chiodini P, Gallo C, Perrone F, de Matteis A (2006) Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial. Br J Cancer 94 (9): 1233-1236. doi: 10.1038/sj.bjc.6603096
28. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406 (6797): 747-752.doi: 10.1038/35021093
29. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 26 (12): 1980-1986. doi: 10.1200/jco.2007.10.8399
30. Radaideh SM, Sledge GW (2008) Taxane versus taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 111 (2): 203-208. doi: 10.1007/s10549-007-9776-4
31. Rosati MS, Raimondi C, Baciarello G, Grassi P, Giovannoni S, Petrelli E, Basile ML, Girolami M, Di Seri M, Frati L (2011) Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II). Ann Oncol 22 (2): 315-320. doi: 10.1093/annonc/mdq392
32. Saad ED, Katz A, Hoff PM, Buyse M (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21 (1): 7-12.doi: 10.1093/annonc/mdp523
33. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen- Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98 (19): 10869-10874. doi: 10.1073/pnas.191367098 (Pubitemid 32878711)
34. Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR (2009) Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol 27 (27): 4522-4529. doi: 10.1200/jco.2008.20.5013
35. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and metaregression. Stat Med 21 (4): 589-624 (Pubitemid 34141379)
36. Vu T, Ellard S, Speers CH, Taylor SC, de Lemos ML, Hu F, Kuik K, Olivotto IA (2008) Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Ann Oncol 19 (3): 461-464. doi: 10.1093/annonc/mdm527 (Pubitemid 351325665)
37. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe- Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M, Delorenzi M (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10 (4): R65. doi: 10.1186/bcr2124
38. Xu HB, Xu Q, Li L (2011) A literature-based meta-analysis taxanebased doublet versus single-agent taxane chemotherapy in patients with advanced breast cancer. J Cancer Res Clin Oncol 137 (6): 1005-1013. doi: 10.1007/s00432-010- 0967-8